Design and Optimization of 3D-Printed Tablets Containing Mucuna Extracts for Erectile Dysfunction Management: A DoE-Guided Study

• Published in: Plants (Basel) Vol. 13; no. 16; p. 2294
• Main Authors: Wattanawiggan, Ratchapoom, Chansakaow, Sunee, Jantrawut, Pensak, Panraksa, Pattaraporn, Jiaranaikulwanitch, Jutamas, Udomsom, Suruk, Worajittiphon, Patnarin, Tipduangta, Pratchaya
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18-08-2024; MDPI
• Subjects: 3-D printers; 3D printing; Controlled release; Copolymers; Design of experiments; Design optimization; Design specifications; DoE; Erectile dysfunction; Extrusion; Formulations; Levodopa; Mucuna; Mucuna extract; Optimization; Polymer blends; Polymers; Polyvinyl alcohol; Printing; Quality of life; Semisolids; Side effects; Slurries; Solidification; sustained release; Tablets; Three dimensional printing; Viscosity; DoE; Mucuna extract; optimization; sustained release; 3D printing; erectile dysfunction
• DOI: 10.3390/plants13162294
• EISSN: 2223-7747

Erectile dysfunction (ED) refers to the inability of the penis to maintain a firm erection during sexual activity. Mucuna, or
, contains levodopa, a compound showing promise in ED treatment. However, formulating Mucuna extract into tablet dosage forms is challenging due to its semisolid nature. This study aimed to develop sustained-release tablets containing Mucuna extract via semisolid extrusion 3D printing. Eudragit RS PO (Eudragit) served as a sustained-release polymer, with poly (vinyl alcohol) (PVA) as a co-polymer for forming the tablet matrices. This study had the following two main phases: screening, which identified the factors affecting the printability, and optimization, which focused on the factors influencing the levodopa release and its consistency. The results showed that both the polymeric solid percentage content (PSPC) in the semisolid slurry and the Eudragit-PVA ratio significantly affected the printability. All of the formulations were printable, and the PSPC and Eudragit-PVA ratios were incorporated into the optimized model. The desired formulation, achieving targeted levodopa release and consistency, had a PSPC of 58.8% and a Eudragit-PVA ratio of 2.87:1. In conclusion, semisolid extrusion 3D printing guided by the design of experiments (DoE) proved feasible for producing reliable 3D-printed tablets with consistent active ingredients and desired release rates.